NCT04750954: Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine tumor (NET)
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients must have progressed on at least one prior systemic cancer treatment with somatostatin analogs; Patients with prior exposure to peptide receptor radionuclide therapy; Patients with known unstable, untreated, or symptomatic central nervous system (brain or leptomeningeal) metastases- see trial for details

Comments are closed.

Up ↑